3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Phase 1
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Gastrointestinal
1
Dermatologic
1
Conditions
Prostatic Neoplasms
4
Neoplasms
3
Sarcoma
2
Lymphoma, Follicular
2
Lymphoma
2
Glioblastoma
2
Uveal Melanoma
1
Uterine Cervical Neoplasms
1
Uterine Cervical Dysplasia
1
Thrombosis
1
Squamous Cell Carcinoma of Head and Neck
1
Solid Tumor, Adult
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Pneumothorax
1
Pituitary Neoplasms
1
Philadelphia Chromosome
1
Pathologic Complete Response
1
Pancreatic Neoplasms
1
Oropharyngeal Neoplasms
1
Opioid-Related Disorders
1
Neoplasms, Plasma Cell
1
Neoplasm Metastasis
1
Myelodysplastic Syndromes
1
Metastatic Castration-resistant Prostate Cancer
1
Meningioma
1
Melanoma
1
Lymphoma, Non-Hodgkin
1
Lung Neoplasms
1
Leukemia, Myeloid, Acute
1
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
1
Interventions
Imatinib Mesylate
12
Sunitinib
4
Leucovorin
3
ripretinib
2
nilotinib
2
avapritinib
2
Oxaliplatin
2
Irinotecan
2
Ipilimumab
2
Fluorouracil
2
CTLA-4 Antigen
2
umbralisib
1
tanespimycin
1
spartalizumab
1
sargramostim
1
ribociclib
1
repaglinide
1
regorafenib
1
pexidartinib
1
olverembatinib
1
binimetinib
1
alvocidib
1
Thalidomide
1
TH 302
1
TAS-116
1
Pharmacogenomic Testing
1
OSI 930
1
Midazolam
1
IDRX-42
1
Gemcitabine
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1
×
Gastrointestinal Stromal Tumors
×
Blood Specimen Collection
×
Clear all
NCT01046487
2026-03-13
PALANGI3
Centre Oscar Lambret
Phase 1
Completed
26 enrolled